Showing 5561-5570 of 9152 results for "".
- DermWire’s AD Pipeline Watch: TDM 180935 Performs Well in Phase 1 Studyhttps://practicaldermatology.com/news/dermwires-ad-pipeline-watch-tdm-180935-performs-well-in-phase-1-study/2462168/Technoderma Medicines, Inc. has completed a Phase 1 clinical trial of TDM-180935 topical ointment for Atopic Dermatitis (AD). TDM 180935 is a small molecule drug candidate that functions as a potent JAK1/Tyk2 small molecule inhibitor. Preclinical assessment of TDM-180935 has demon
- Revealed: How Chronological Aging Affects EV Production by Human Keratinocyteshttps://practicaldermatology.com/news/revealed-how-chronological-aging-affects-ev-production-by-human-keratinocytes/2462166/Aging modulates extracellular vesicles of epidermal keratinocytes, new research in Aging suggests. The disturbance of intercellular communication is one of the hallmarks of aging. In their new study, researchers from
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but
- Zeroing in on What Causes Melanoma to Spread to the Brainhttps://practicaldermatology.com/news/zeroing-in-on-what-causes-melanoma-to-spread-to-the-brain/2462160/More than half of patients with advanced melanoma will see the disease spread to the brain, where it rapidly progresses, often leading to death in only three to four months. Researchers in Moffitt Cancer Center’s
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Taking a Joint Approach to Treating PsA and PsO: One Rheumatologist’s Advice on Working With Dermatologistshttps://practicaldermatology.com/news/taking-a-joint-approach-to-treating-psa-and-pso-one-rheumatologists-advice-on-working-with-dermatologists/2462158/Psoriasis (PsO) and psoriatic arthritis (PsA) often travel together, which is why dermatologists and rheumatologists need to collaborate and ensure that patients receive the best and most appropriate care for their skin and joints. Around one in three people with PsO also have PsA, acco
- Regenerative Medicine in Action: Reprogramming Tissue Mechanically to Heal Wounds, Rejuvenate Skinhttps://practicaldermatology.com/news/regenerative-medicine-in-action-reprogramming-tissue-mechanically-to-heal-wounds-rejuvenate-skin/2462156/Researchers have taken connective tissue cells that have been mechanically reprogrammed to resemble stem cells and transplanted them into damaged skin. In their laboratory experiment, they were able to show that the skin tissue model can actually be rejuvenated and that injur
- AD Pipeline Watch: Oral Zelnecirnon Shows Early Promise in ADhttps://practicaldermatology.com/news/ad-pipeline-watch-oral-zelnecirnon-shows-early-promise-in-ad/2462153/Zelnecirnon performed well in a Phase 1a/1b clinical trial of atopic dermatitis (AD), RAPT Therapeutics reports. Zelnecirnon is a small molecule oral therapy designed to selectively inhibit the migration of Th2 cells into inflamed tissues by blocking CCR4, a receptor highly express
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At
- First Patients Enrolled in Phase 2 Proof of Concept Trial of MC2-25 VLS in Vulvar Lichen Sclerosushttps://practicaldermatology.com/news/first-patients-enrolled-in-phase-2-proof-of-concept-trial-of-mc2-25-vls-in-vulvar-lichen-sclerosus/2462151/The first patients have been enrolled in a Phase 2a proof of concept trial evaluating the safety and efficacy of MC2-25 VLS, a new drug candidate for the treatment of urea- associated skin diseases, including vulvar lichen sclerosus. MC2-25 VLS is a based on a di-peptide that